Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Enterprise Value to FCFF (EV/FCFF)
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
An examination of the investment activity ratios reveals consistent, though generally subtle, shifts over the observed period. The net fixed asset turnover, total asset turnover, and equity turnover ratios all demonstrate discernible trends, indicating evolving efficiency in asset utilization. Overall, a slight decline in asset efficiency is apparent towards the end of the analyzed timeframe.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio began at 4.87 and generally increased through October 1, 2022, peaking at 5.12. Following this, the ratio experienced a gradual decline, reaching 4.22 by December 31, 2025. While fluctuations occurred quarterly, the overall trend is downward, suggesting a decreasing ability to generate sales from fixed assets over time. The most significant declines occurred between September 30, 2023, and December 31, 2025.
- Total Asset Turnover
- The total asset turnover ratio exhibited a similar pattern to the net fixed asset turnover, initially increasing from 0.44 to 0.49 by October 1, 2022. Subsequently, it experienced a consistent, albeit moderate, decline, ending at 0.40 on December 31, 2025. This indicates a diminishing capacity to generate sales revenue from all assets held by the company. The rate of decline appeared to accelerate in the latter half of the period.
- Equity Turnover
- The equity turnover ratio showed an initial increase from 1.00 to 1.04 by April 1, 2023, before commencing a steady decline. By December 31, 2025, the ratio reached 0.83. This suggests a decreasing efficiency in generating sales revenue from shareholder equity. The decline, while consistent, was less pronounced than that observed in the total asset turnover ratio.
The concurrent downward trends in all three ratios suggest a systemic shift in how effectively assets are being utilized to generate revenue. Further investigation would be required to determine the underlying causes of these trends, such as changes in industry dynamics, internal operational adjustments, or investment strategies.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Net fixed asset turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Property, plant and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio exhibits a generally declining trend over the observed period, although with some fluctuations. Initially, the ratio demonstrates a slight increase from 4.87 to 5.12 between April 2022 and October 2022. Subsequently, it experiences a decrease, falling to 4.54 by December 2023. This downward movement continues into 2024 and 2025, reaching 4.22 in December 2025, representing the lowest point in the analyzed timeframe.
- Overall Trend
- A consistent, albeit gradual, decline in the net fixed asset turnover ratio is apparent. This suggests that the company is generating less revenue per dollar of net fixed assets over time. While the initial values are relatively stable, the latter portion of the period shows a more pronounced decrease.
- Short-Term Fluctuations
- Despite the overall downward trend, there are short-term variations. For example, the ratio remains consistent between April 2023 and July 2023 at 4.68. Similarly, the ratio between April 1, 2024 and June 29, 2024 remains stable at 4.56. These periods of stability are interspersed with declines, indicating that the trend is not entirely linear.
- Recent Performance
- The most recent quarters (September 2024 through December 2025) show the most significant declines. The ratio decreased from 4.50 in September 2024 to 4.22 in December 2025. This recent performance warrants further investigation to understand the underlying drivers of this reduction.
- Revenue and Asset Relationship
- Revenues generally remain relatively stable throughout the period, with a noticeable increase in December 2024 and a larger increase in December 2025. However, the growth in net property, plant, and equipment consistently outpaces revenue growth, contributing to the observed decline in the net fixed asset turnover ratio. This suggests the company is investing in fixed assets at a rate faster than revenue is increasing.
In conclusion, the net fixed asset turnover ratio indicates a decreasing efficiency in utilizing fixed assets to generate revenue. The recent acceleration of this decline suggests a potential need for review of asset utilization strategies and investment decisions.
Total Asset Turnover
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Total asset turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a generally declining trend over the observed period, though with some fluctuation. Initially, the ratio increased from 0.44 in April 2022 to a peak of 0.49 in October 2022. Subsequently, it experienced a period of relative stability, followed by a gradual decrease towards the end of the observation window.
- Initial Increase (Apr 2, 2022 – Oct 1, 2022)
- The ratio demonstrated improvement during this timeframe, suggesting increasing efficiency in utilizing assets to generate revenue. This could be attributed to increased sales volume or improved asset management practices.
- Stabilization and Decline (Oct 1, 2022 – Jun 29, 2024)
- Following the peak in October 2022, the ratio stabilized around the 0.45-0.46 range for several quarters before beginning a slow decline. This suggests that while asset utilization remained relatively consistent, revenue growth did not keep pace with asset growth.
- Accelerated Decline (Jun 29, 2024 – Dec 31, 2025)
- A more pronounced downward trend is observed in the latter part of the period, with the ratio decreasing from 0.42 in June 2024 to 0.40 in December 2025. This indicates a weakening relationship between revenue and total assets, potentially signaling decreasing operational efficiency or an increase in asset investment without a corresponding increase in sales.
- Revenue and Asset Relationship
- While revenues fluctuate, they generally remain within a relatively narrow range throughout the period. However, total assets consistently increase, particularly towards the end of the observation window. The declining asset turnover ratio suggests that the growth in assets is outpacing revenue growth, indicating a potential need to evaluate asset allocation and utilization strategies.
The observed trend warrants further investigation to determine the underlying causes of the declining asset turnover. Factors such as changes in industry dynamics, capital expenditure decisions, and working capital management should be considered to understand the implications for future performance.
Equity Turnover
| Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q4 2025 Calculation
Equity turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio for the analyzed period demonstrates a generally decreasing trend, although with some fluctuation. Initially, the ratio remained relatively stable before exhibiting a more pronounced decline in later quarters. This suggests a diminishing efficiency in generating revenue from shareholders’ equity over time.
- Overall Trend
- The equity turnover ratio began at 1.00 in April 2022 and generally decreased to 0.83 by December 2025. While there were periods of slight increases, the overall trajectory points towards a lower level of revenue generation per dollar of equity.
- Initial Stability (Apr 2022 - Dec 2022)
- From April 2022 through December 2022, the ratio fluctuated within a narrow range, moving from 1.00 to 1.02. This indicates a consistent, albeit modest, level of revenue generation relative to equity during this period. The slight increase suggests a marginal improvement in efficiency.
- Declining Phase (Apr 2023 - Dec 2025)
- Beginning in April 2023, a more noticeable downward trend emerged. The ratio decreased from 1.04 to 0.99 in July 2023, then continued to decline, reaching 0.83 by December 2025. This suggests that the company is generating less revenue for each dollar of equity invested over this timeframe. The most significant declines occurred between October 2022 and December 2023.
- Recent Stabilization
- From September 2024 through December 2025, the ratio remained relatively stable, fluctuating between 0.83 and 0.86. This suggests a potential leveling off of the declining trend, although the ratio remains significantly lower than its initial values.
The observed decrease in equity turnover warrants further investigation. Potential contributing factors could include changes in asset utilization, profitability, or financial leverage. A comprehensive analysis of related financial metrics is recommended to understand the underlying drivers of this trend.